Compare Crispr Therapeutics AG (CRSP) vs iShares Bitcoin Trust (IBIT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Crispr Therapeutics AG vs iShares Bitcoin Trust — how do they compare? Crispr Therapeutics AG trades at $50.93 (market cap $4.97B), while iShares Bitcoin Trust trades at $36.97. The key difference: Crispr Therapeutics AG is trading nearer its 52-week high, iShares Bitcoin Trust nearer its low. Which is the better fit depends on your goals.
| CRSP | IBIT | |
|---|---|---|
Market Cap | $4.97B | — |
Sector | Health | Crypto-linked |
52-Week High | $76.78 | $71.29 |
52-Week Low | $44.34 | $33.29 |
Enterprise Value | $3.32B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
CRSP trades at $50.63, down 5.1% over 24 hours, amid a bearish technical signal. The company shows deep losses with a net income margin of -56,853.4% in 2025 and negative cash flow from operations. However, analyst consensus remains optimistic with a $74.50 price target, and recent news highlights FDA approval for Casgevy, expanding its gene therapy market.
The outlook hinges on commercial execution of Casgevy and pipeline progress, offering high growth potential in gene editing. Key risks include sustained cash burn, competitive pressures, and regulatory hurdles. Despite current financial challenges, strong analyst buy ratings suggest confidence in long-term value.
IBIT trades at $35.22, down 2.79% today, reflecting recent bearish pressure. Technical indicators show a predominantly bearish trend with moving averages signaling sell conditions, while oscillators remain neutral. The stock faces resistance at $36 and finds support at $35. Recent news highlights IBIT's position as a leading Bitcoin ETF with $44.9 billion in assets under management, surpassing competitors like Fidelity's offering as of June 29, 2026 (The Motley Fool).
The outlook for IBIT hinges on Bitcoin ETF flows and market sentiment toward crypto assets. Investment opportunities include its dominant market share and low expense ratio, but risks involve significant outflows from Bitcoin ETFs, with a record $4.5 billion in June 2026 (Zacks Investment Research, July 6, 2026), and volatility linked to cryptocurrency price swings.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Crispr Therapeutics AG
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →About iShares Bitcoin Trust
IBIT is a spot Bitcoin ETF that tracks the price of Bitcoin directly. Managed by BlackRock, it offers investors a regulated way to gain exposure to the digital asset within a traditional brokerage account.
Read more on IBIT →
